4-Chloro-6-Iodoquinazoline CAS 98556-31-1 Tsafta > 98.0% (HPLC)

4-Chloro-6-Iodoquinazoline (CAS: 98556-31-1) matsakaici ne a cikin haɗin Lapatinib (CAS: 231277-92-2) / Lapatinib Ditosylate Monohydrate (CAS: 388082-78-8).
Lapatinib wani sabon maganin cutar kansar nono ne wanda GlaxoSmithKline ya ƙera kuma ya ƙera shi, wanda Hukumar Abinci da Magunguna ta Amurka ta amince da ita a ranar 13 ga Maris, 2007. Alamar da aka amince da ita a halin yanzu tana haɗe da capecitabine don ci gaba ko cutar kansar nono, da masu ciwon nono. dole ne a bi da su tare da wasu magunguna na farko.Sunan kasuwancinsa a Amurka shine Tykerb.Ranar 14 ga Disamba, 2007, Hukumar Kula da Magunguna ta Turai (EMEA) ta amince da lissafin Lapatinib a Turai a ƙarƙashin sunan kasuwanci Tyverb.Magungunan da aka yi niyya na kwayoyin halitta don ciwon nono yana nufin maganin oncogenes da samfuran maganganun da ke da alaƙa da abin da ya faru da haɓakar ciwon nono.Kwayoyin da aka yi niyya na ƙwayoyin cuta suna hana ko kashe ƙwayoyin ƙari ta hanyar toshe siginar sigina a cikin ƙwayoyin ƙari ko ƙwayoyin da ke da alaƙa don sarrafa canje-canje a cikin maganganun kwayoyin halitta.Lapatinib wani ƙananan ƙwayoyin ƙwayoyin epidermal girma factor tyrosine kinase inhibitor na baka.Gwaje-gwaje na asibiti sun nuna cewa ga masu ciwon daji na HER2 waɗanda suka haɓaka juriya ga Roche's Herceptin (Herceptin), Lapatinib yana da sakamako mai kyau na asibiti.Gwaje-gwajen in vitro, Lapatinib yana da tasirin hana haɓakar haɓakar haɓakar haɓakar ƙwayoyin cutar kansar nono na Her-2.A cikin gwaji na Mataki na I na ci-gaba da ciwon nono tare da wuce gona da iri na Her-2, Lapatinib shima yana da babban tasiri kuma ba shi da juriya ga Herceptin (trastuzumab).Domin tsarinsa ƙaramin ƙwayar ƙwayar cuta ne, sabanin Herceptin (trastuzumab), yana iya shiga shingen jini-kwakwalwa kuma yana da wani tasiri na warkewa akan metastasis na ƙwayar nono.